ClinConnect ClinConnect Logo
Search / Trial NCT06694012

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

Launched by OSAKA METROPOLITAN UNIVERSITY · Nov 15, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Type 2 Diabetes Mellitus Hypertension Hyperlipidemia Dyslipidemia Hyperuricemia Obesity Abdominal Obesity Visceral Fat Visceral Adiposity Chronic Kidney Disease Japanese Metabolic Syndrome Insulin Sensitivity Insulin Resistance

ClinConnect Summary

The Osaka Cardiometabolic Epidemiological Study, specifically the Ohtori Study Part 2, is looking to understand how the distribution of body fat in people affects their risk of developing metabolic and heart diseases. This study is focused on Japanese men and women and will use CT scans to measure body fat, along with other tests to discover new risk factors for these health issues.

The study is currently recruiting participants aged 30 and older, regardless of gender. If you join the study, you can expect to undergo some tests and assessments that will help researchers gather important information. It's important to note that women who might be pregnant are not eligible to participate. This research aims to help improve our understanding of how body fat and other factors contribute to conditions like diabetes, obesity, and heart disease.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • -
  • Exclusion Criteria:
  • Women who may be pregnant

About Osaka Metropolitan University

Osaka Metropolitan University is a leading academic institution in Japan that emphasizes innovative research and development in the field of healthcare. As a clinical trial sponsor, the university leverages its extensive expertise in biomedical sciences and collaboration with multidisciplinary teams to advance medical knowledge and improve patient outcomes. The institution is committed to conducting rigorous and ethically sound clinical trials that contribute to the understanding of various diseases and the efficacy of new treatments, thereby fostering advancements in public health and clinical practice.

Locations

Sakai, Osaka, Japan

Patients applied

0 patients applied

Trial Officials

Tomoshige Hayashi, MD, PhD

Principal Investigator

Osaka Metropolitan University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported